Table 2.
Genotype frequencies in men group according to cases and controls
| Polymorphism | Cases A | Cases B | Controlsa | ORb | CI 95 % | Cases vs. controls | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||||||
| HLA-G 14 bp ins/del | del/del | 29 | 36.7 | 61 | 30.8 | 75 | 34.2 | 1 |
χ
2df=4 = 1.57 p = 0.8136 |
||
| del/ins | 30 | 38 | 81 | 40.9 | 91 | 41.6 | 1.02 | 0.67 | 1.53 | ||
| ins/ins | 20 | 25.3 | 56 | 28.3 | 53 | 24.2 | 1.19 | 0.75 | 1.90 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.0418 | p = 0.0107 | p = 0.02 | ||||||||
| f | 0.23 | 0.18 | 0.16 | ||||||||
| HLA-G −725 | CC | 43 | 54.5 | 142 | 71.7 | 145 | 66.2 | 1 |
χ
2df=6 = 11.1 p = 0.1959 |
||
| CG | 31 | 39.2 | 46 | 23.3 | 55 | 25.1 | 1.10 | 0.73 | 1.65 | ||
| CT | 3 | 3.8 | 6 | 3 | 12 | 5.5 | 0.60 | 0.25 | 1.42 | ||
| GG | 2 | 2.5 | 3 | 1.5 | 5 | 2.3 | 0.78 | 0.24 | 2.61 | ||
| GT | 0 | 0 | 1 | 0.5 | 2 | 0.9 | 0.47 | – | – | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.5701 | p = 0.9154 | p = 0.9989 | ||||||||
| f | –0.09 | –0.008 | 0.008 | ||||||||
| HLA-G −716 | TT | 28 | 35.4 | 42 | 21.2 | 52 | 23.7 | 1 |
χ
2df=4 = 7.76 p = 0.1008 |
||
| GT | 27 | 34.2 | 95 | 48 | 105 | 47.9 | 0.86 | 0.56 | 1.35 | ||
| GG | 24 | 30.4 | 61 | 30.8 | 62 | 28.3 | 1.02 | 0.63 | 1.65 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.0064 | p = 0.6681 | p = 0.5885 | ||||||||
| f | 0.314 | 0.031 | 0.039 | ||||||||
| KIR2DL4 9620 | 9A/9A | 22 | 27.8 | 59 | 29.8 | 74 | 33.8 | 1 |
χ
2df=4 = 4.12 p = 0.3904 |
||
| 9A/10A | 42 | 53.2 | 103 | 52 | 95 | 43.4 | 1.39 | 0.93 | 2.09 | ||
| 10A/10A | 15 | 19 | 36 | 18.2 | 50 | 22.8 | 0.93 | 0.57 | 1.54 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.651 | p = 0.4747 | p = 0.0756 | ||||||||
| f | –0.072 | –0.055 | 0.122 | ||||||||
| KIR2DL4 9571 | TT | 22 | 27.8 | 59 | 29.8 | 78 | 35.6 | 1 |
χ
2 = 4.1 p = 0.3921 |
||
| CT | 42 | 53.2 | 103 | 52 | 95 | 43.4 | 1.47 | 0.98 | 2.20 | ||
| CC | 15 | 19 | 36 | 18.2 | 46 | 21 | 1.07 | 0.64 | 1.76 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.651 | p = 0.4747 | p = 0.0979 | ||||||||
| f | –0.072 | –0.055 | 0.113 | ||||||||
| KIR2DL4 9769 | CC | 53 | 67.1 | 144 | 72.7 | 170 | 77.6 | 1 |
χ
2df=4 = 4.07 p = 0.4033 |
||
| CA | 23 | 29.1 | 45 | 22.7 | 42 | 19.2 | 1.39 | 0.90 | 2.15 | ||
| AA | 3 | 3.8 | 9 | 4.6 | 7 | 3.2 | 1.44 | 0.57 | 3.64 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.7153 | p = 0.0568 | p = 0.0597 | ||||||||
| f | 0.028 | 0.15 | 0.14 | ||||||||
| KIR2DL4 9797 | GG | 22 | 27.8 | 56 | 28.3 | 77 | 35.2 | 1 |
χ
2df=4 = 4.6 p = 0.3304 |
||
| GA | 42 | 53.2 | 107 | 54 | 97 | 44.3 | 1.51 | 1.01 | 2.27 | ||
| AA | 15 | 19 | 35 | 17.7 | 45 | 20.5 | 1.10 | 0.66 | 1.82 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.651 | p = 0.2495 | p = 0.168 | ||||||||
| f | –0.072 | –0.093 | 0.095 | ||||||||
| LILRB1 5651 | GG | 66 | 83.5 | 162 | 81.8 | 190 | 86.7 | 1 |
χ
2df=4 = 2.24 p = 0.6987 |
||
| GA | 10 | 12.7 | 28 | 14.1 | 24 | 11 | 1.31 | 0.76 | 2.25 | ||
| AA | 3 | 3.8 | 8 | 4.1 | 5 | 2.3 | 1.74 | 0.62 | 4.90 | ||
| ∑ | 79 | 100 | 198 | 100 | 219 | 100 | |||||
| H-W | p = 0.026 | p = 0.0006 | p = 0.0046 | ||||||||
| f | 0.3 | 0.28 | 0.235 | ||||||||
Cases A patients with two miscarriages; Cases B patients with three or more miscarriages, N number of cases, P probability, OR odds ratio, 95 % CI confidence interval, H-W Hardy–Weinberg equilibrium, f < 0 correspond to deficiency of homozygotes, f > 0 correspond to excess of homozygotes, f = 0 in case of H-W
a Frequencies of KIR2DL4 polymorphisms in Controls were described previously by Nowak et al. (2015). b Odds ratio computed for [cases A plus cases B] vs. controls